CN112679613A - 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 - Google Patents
骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 Download PDFInfo
- Publication number
- CN112679613A CN112679613A CN202110270092.5A CN202110270092A CN112679613A CN 112679613 A CN112679613 A CN 112679613A CN 202110270092 A CN202110270092 A CN 202110270092A CN 112679613 A CN112679613 A CN 112679613A
- Authority
- CN
- China
- Prior art keywords
- ser
- variable region
- chain variable
- gly
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
抗体名称 | 抗体效价 |
2D3 | 5.12×10<sup>6</sup> |
3E2 | 2.56×10<sup>6</sup> |
4D3 | 5.12×10<sup>6</sup> |
4D6 | 5.12×10<sup>6</sup> |
5A3 | 2.56×10<sup>6</sup> |
5D7 | 5.12×10<sup>6</sup> |
6F4 | 2.56×10<sup>6</sup> |
6G5 | 5.12×10<sup>6</sup> |
抗体名称 | KD(nM) |
2D3 | 0.23 |
3E2 | 0.56 |
4D3 | 0.29 |
4D6 | 0.31 |
5A3 | 0.58 |
5D7 | 0.45 |
6F4 | 0.62 |
6G5 | 0.34 |
Claims (10)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110469571.XA CN112940129A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469566.9A CN112940128A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469570.5A CN113087800A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469520.7A CN112940127A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469518.XA CN112940126A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110270092.5A CN112679613B (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469604.0A CN113004410A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469513.7A CN113004409A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110270092.5A CN112679613B (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
Related Child Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110469518.XA Division CN112940126A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469570.5A Division CN113087800A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469566.9A Division CN112940128A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469520.7A Division CN112940127A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469571.XA Division CN112940129A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469604.0A Division CN113004410A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469513.7A Division CN113004409A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112679613A true CN112679613A (zh) | 2021-04-20 |
CN112679613B CN112679613B (zh) | 2021-10-01 |
Family
ID=75455526
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110469570.5A Withdrawn CN113087800A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469518.XA Withdrawn CN112940126A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469566.9A Withdrawn CN112940128A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469604.0A Withdrawn CN113004410A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469571.XA Withdrawn CN112940129A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110270092.5A Active CN112679613B (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469520.7A Withdrawn CN112940127A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469513.7A Withdrawn CN113004409A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110469570.5A Withdrawn CN113087800A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469518.XA Withdrawn CN112940126A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469566.9A Withdrawn CN112940128A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469604.0A Withdrawn CN113004410A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469571.XA Withdrawn CN112940129A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110469520.7A Withdrawn CN112940127A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
CN202110469513.7A Withdrawn CN113004409A (zh) | 2021-03-12 | 2021-03-12 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (8) | CN113087800A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115109161A (zh) * | 2022-06-28 | 2022-09-27 | 北京仁立竞合生物科技有限公司 | 含有间充质干细胞的减肥药物组合物 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115028730B (zh) * | 2022-05-17 | 2022-11-08 | 诺赛联合(北京)生物医学科技有限公司 | 一种成体干细胞衍生的类器官制备方法 |
CN115010807B (zh) * | 2022-06-29 | 2023-10-17 | 广东赛尔生物科技有限公司 | 单克隆抗体和载药的干细胞在制备治疗宫颈癌的药物中的应用 |
CN115975036B (zh) * | 2022-08-18 | 2023-06-09 | 北京诺赛国际医学研究院 | 包含干细胞的药物组合物及其治疗癌症的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080226613A1 (en) * | 2003-04-18 | 2008-09-18 | University Of Massachusetts | Prognosis, diagnosis and treatment of bone marrow derived stem cell associated cancer |
US20100196327A1 (en) * | 2007-04-11 | 2010-08-05 | Cell Science Systems | Methods for diagnosing biological samples containing stem cells |
WO2018036561A1 (en) * | 2016-08-26 | 2018-03-01 | Beigene, Ltd. | Anti-tim-3 antibodies and use thereof |
-
2021
- 2021-03-12 CN CN202110469570.5A patent/CN113087800A/zh not_active Withdrawn
- 2021-03-12 CN CN202110469518.XA patent/CN112940126A/zh not_active Withdrawn
- 2021-03-12 CN CN202110469566.9A patent/CN112940128A/zh not_active Withdrawn
- 2021-03-12 CN CN202110469604.0A patent/CN113004410A/zh not_active Withdrawn
- 2021-03-12 CN CN202110469571.XA patent/CN112940129A/zh not_active Withdrawn
- 2021-03-12 CN CN202110270092.5A patent/CN112679613B/zh active Active
- 2021-03-12 CN CN202110469520.7A patent/CN112940127A/zh not_active Withdrawn
- 2021-03-12 CN CN202110469513.7A patent/CN113004409A/zh not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080226613A1 (en) * | 2003-04-18 | 2008-09-18 | University Of Massachusetts | Prognosis, diagnosis and treatment of bone marrow derived stem cell associated cancer |
US20100196327A1 (en) * | 2007-04-11 | 2010-08-05 | Cell Science Systems | Methods for diagnosing biological samples containing stem cells |
WO2018036561A1 (en) * | 2016-08-26 | 2018-03-01 | Beigene, Ltd. | Anti-tim-3 antibodies and use thereof |
Non-Patent Citations (1)
Title |
---|
李京云 等: "多西紫杉醇与骨髓间充质干细胞联合干预对人肝癌细胞株SMMC-7721的影响", 《中国组织工程研究》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115109161A (zh) * | 2022-06-28 | 2022-09-27 | 北京仁立竞合生物科技有限公司 | 含有间充质干细胞的减肥药物组合物 |
CN115109161B (zh) * | 2022-06-28 | 2023-08-11 | 广东赛尔生物科技有限公司 | 含有间充质干细胞的减肥药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN112940128A (zh) | 2021-06-11 |
CN112679613B (zh) | 2021-10-01 |
CN113004410A (zh) | 2021-06-22 |
CN113004409A (zh) | 2021-06-22 |
CN113087800A (zh) | 2021-07-09 |
CN112940127A (zh) | 2021-06-11 |
CN112940129A (zh) | 2021-06-11 |
CN112940126A (zh) | 2021-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112679613B (zh) | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 | |
AU2015314316B2 (en) | Cross reactive Siglec antibodies | |
JP2022513383A (ja) | 二重特異性抗体及びその作製方法と使用 | |
SK283133B6 (sk) | Bišpecifická molekula použiteľná na lýzu nádorových buniek, spôsob jej prípravy, monoklonálna protilátka, farmaceutický prípravok, kit a spôsob čistenia nádorových buniek | |
CN109776678A (zh) | 一种人源化pd-l1单克隆抗体、其制备方法和应用 | |
WO2022007650A1 (zh) | 靶向bcma和cd19的嵌合抗原受体car或car构建体及其应用 | |
TW202115122A (zh) | 抗b7-h3抗體及其應用 | |
CN110922486B (zh) | 一种分离的结合抗原psma的蛋白及其用途 | |
CN110172090B (zh) | Cd134单克隆抗体及其制备方法和癌症治疗中的应用 | |
US20210317230A1 (en) | Fusion protein and use thereof | |
CN113402607B (zh) | 一种抗lap单克隆抗体、其抗原结合片段及其应用 | |
CN109232740B (zh) | 一种抗pd-l1抗体及其在抗肿瘤治疗中的应用 | |
JP2021533770A (ja) | 抗IL−1β抗体およびその医薬組成物およびそれらの使用 | |
CN107400165A (zh) | 一种il‑13抗体及其制备方法和应用 | |
WO2023280297A1 (zh) | Cd19抗体及其应用 | |
US20230406921A1 (en) | Antibody and preparation method therefor | |
CN111205370B (zh) | 抗ptn抗体在抑制白血病干细胞以及治疗慢性粒细胞白血病中的应用 | |
CN111303288B (zh) | 一种分离的结合抗原psma的蛋白及其用途 | |
WO2015042807A1 (zh) | 抗cd20的全人源单克隆抗体及其应用 | |
CN116589588B (zh) | 结合凝血因子x的抗体 | |
CN111234021B (zh) | 一种抗ccr5抗体及其在治疗肿瘤中的应用 | |
CN116948023B (zh) | Tau蛋白抗体及其应用 | |
WO2024078381A1 (zh) | 结合人cd39的抗体或其抗原结合片段、其制备方法及用途 | |
EP3954711A1 (en) | Bispecific antibody specifically binding to gpnmb and cd3, and use thereof | |
KR101042579B1 (ko) | 아이소타입 이뮤노글로빈 에이인 신규한 rbp4 특이적인 항체 ag102 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Xie Peizeng Inventor after: Yang Zhejun Inventor after: Deng Yin Inventor after: Liu Huan Inventor after: Zhu Xiaoming Inventor before: Liu Huan Inventor before: Zhu Xiaoming |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210910 Address after: 510700 Room 308, building 4, No. 2, scientific research road, Science City, Huangpu District, Guangzhou City, Guangdong Province Applicant after: Guangdong xinzhengcheng Life Science Co.,Ltd. Applicant after: Ningbo junshuo Technology Development Co.,Ltd. Address before: 701-286, floor 7, building 1, No. 5, guangyuanzha, Haidian District, Beijing 100081 Applicant before: Beijing Guangwei Biotechnology Co., Ltd |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211222 Address after: 518000 room 2102, building 7, Qianhai excellence Financial Center (phase I), unit 2, guiwan area, Nanshan street, Qianhai Shenzhen Hong Kong cooperation zone, Shenzhen, Guangdong Patentee after: Shenzhen xinzhengcheng Life Science Research Institute Co.,Ltd. Address before: 510700 Room 308, building 4, No. 2, scientific research road, Science City, Huangpu District, Guangzhou City, Guangdong Province Patentee before: Guangdong xinzhengcheng Life Science Co.,Ltd. Patentee before: Ningbo junshuo Technology Development Co., Ltd |